📣 VC round data is live. Check it out!
- Public Comps
- Sinopep
Sinopep Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sinopep and similar public comparables like Semnur Pharmaceuticals, Inhibrx Biosciences, Idorsia, Precigen and more.
Sinopep Overview
About Sinopep
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
Founded
2009
HQ

Employees
N/A
Website
Financials (FY)
EV
$2B
Valuation Multiples
Start free trialSinopep Financials
Sinopep reported last fiscal year revenue of $287M and EBITDA of $110M.
In the same fiscal year, Sinopep generated $180M in gross profit, $110M in EBITDA, and $49M in net income.
Revenue (LTM)
Sinopep P&L
In the most recent fiscal year, Sinopep reported revenue of $287M and EBITDA of $110M.
Sinopep is profitable as of last fiscal year, with gross margin of 63%, EBITDA margin of 38%, and net margin of 17%.
Financial data powered by Morningstar, Inc.
Sinopep Stock Performance
Sinopep has current market cap of $1B, and enterprise value of $2B.
Market Cap Evolution
Sinopep's stock price is $4.37.
Sinopep share price decreased by 0.7% in the last 30 days, and by 19.2% in the last year.
Sinopep has an EPS (earnings per share) of $0.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $1B | -1.6% | -0.7% | 2.5% | -19.2% | $0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSinopep Valuation Multiples
Sinopep trades at 5.7x EV/Revenue multiple, and 14.9x EV/EBITDA.
EV / Revenue (LTM)
Sinopep Financial Valuation Multiples
As of June 4, 2026, Sinopep has market cap of $1B and EV of $2B.
Sinopep has a P/E ratio of 28.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sinopep Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Sinopep Margins & Growth Rates
In the most recent fiscal year, Sinopep reported gross margin of 63%, EBITDA margin of 38%, and net margin of 17%.
Sinopep Margins
Sinopep Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Sinopep Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Sinopep Competitors
Sinopep competitors include Semnur Pharmaceuticals, Inhibrx Biosciences, Idorsia, Precigen, Immatics, Uniphar, ArriVent BioPharma, Ardelyx, Celltrion Pharm and Septerna.
Most Sinopep public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | |||
| 1072.6x | 1855.4x | (11.1x) | - | |||
| 10.5x | 10.3x | (50.7x) | (35.9x) | |||
| 146.1x | 24.3x | (12.7x) | (20.8x) | |||
| 15.3x | 17.0x | (4.4x) | (3.7x) | |||
| 0.5x | 0.5x | 11.6x | 11.1x | |||
| - | - | (6.0x) | (5.9x) | |||
| 3.3x | 2.9x | (45.7x) | (107.1x) | |||
This data is available for Pro users. Sign up to see all Sinopep competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sinopep
| When was Sinopep founded? | Sinopep was founded in 2009. |
| Where is Sinopep headquartered? | Sinopep is headquartered in China. |
| Is Sinopep publicly listed? | Yes, Sinopep is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Sinopep? | Sinopep trades under 688076 ticker. |
| When did Sinopep go public? | Sinopep went public in 2021. |
| Who are competitors of Sinopep? | Sinopep main competitors include Semnur Pharmaceuticals, Inhibrx Biosciences, Idorsia, Precigen, Immatics, Uniphar, ArriVent BioPharma, Ardelyx, Celltrion Pharm, Septerna. |
| What is the current market cap of Sinopep? | Sinopep's current market cap is $1B. |
| What is the current revenue of Sinopep? | Sinopep's last fiscal year revenue is $287M. |
| What is the current EV/Revenue multiple of Sinopep? | Current revenue multiple of Sinopep is 5.7x. |
| Is Sinopep profitable? | No, Sinopep is not profitable. |
| How many companies Sinopep has acquired to date? | Sinopep hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Sinopep has invested to date? | Sinopep hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Sinopep
Lists including Sinopep
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.